GSK2586184 clinical trials
Also written GLPG0778.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How each study uses GSK2586184 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- GLPG0778
- 2
Studies by the year they started
7 studies that test it; most in 2013 (4)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses GSK2586184 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184CompletedPhase 1GlaxoSmithKlineNCT01953835Written as GSK2586184 standard formulation
- Safety and Tolerability Study of GSK2586184 in Patients With Moderate to Severely Active Ulcerative Colitis.TerminatedPhase 1GlaxoSmithKlineNCT02000453Written as GSK2586184 400mg
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK2586184 and the Effect of Food and GenderCompletedPhase 1GlaxoSmithKlineNCT01687309Written as GSK2586184 800mg single and repeat dose
- A Dose Ranging Study to Evaluate the Safety and Efficacy of GSK2586184 in Patients With Chronic Plaque PsoriasisCompletedPhase 2GlaxoSmithKlineNCT01782664Written as 100 mg GSK2586184
- An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184TerminatedPhase 2GlaxoSmithKlineNCT01777256Written as GSK2586184 50 mg
- GLPG0778: Multiple Ascending Oral Doses, Pharmacokinetic, Safety, and Pharmacodynamic StudyCompletedPhase 1Galapagos NVNCT01336244Written as GLPG0778
- First-in-Human Single Ascending and Multiple Dose of GLPG0778CompletedPhase 1Galapagos NVNCT01278108Written as GLPG0778